Their quality of life on dialysis is in YOUR hands
HDx: your opportunity to make a difference to your patients’ quality of life
Patient-reported symptom burden has a significant impact on patient quality of life.1 How can expanded haemodialysis (HDx), enabled by MCO Theranova, make a difference for your patients?
A better night’s sleep
Uraemic pruritis has a major impact on patients’ lives. The poor sleep quality caused by uraemic pruritis has been linked to subsequent poor quality of life and higher mortality risk.2
One randomised clinical study found HDx to deliver statistically significant improvements in key aspects of patient-reported uremic pruritus compared to conventional HD.3
Energy to enjoy more of life
Most people on HD report a high symptom burden, with fatigue and a lack of energy interfering with patients’ daily lives.
A 2021 study comparing HD to HDx showed that HDx therapy may significantly reduce dialysis recovery time and improve perceived fatigue level.4
Innovation is in your hands
HDx therapy is enabled by the innovative MCO membrane in the Theranova dialyser. With its patented Molecular Weight Retention Onset (MWRO) and Molecular Weight Cut-Off (MWCO) range, Theranova provides superior removal of large-middle molecules compared to HD and HDF therapies.5,6,7,8
Efficient removal of some large-middle molecules may be associated with relieving the symptom burden for patients, such as better sleep quality and improved energy levels.3,4 These improvements may help improve patients’ overall quality of life.